Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 4Neoplasms 3Sarcoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Adenocarcinoma of Lung 2Stomach Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Glioma 1EGFR-mutant Non-small Cell Lung Cancer 1Carcinoma 1Bronchial Neoplasms 1

Interventions

pembrolizumab 25Cisplatin 23Carboplatin 18Magnetic Resonance Spectroscopy 16Paclitaxel 15Specimen Handling 14Pemetrexed 11durvalumab 9Radiotherapy, Intensity-Modulated 8Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Nivolumab 7Radiation 6Docetaxel 6Cetuximab 6Biopsy 6osimertinib 5cemiplimab 5Taxes 5Radiotherapy 5Ipilimumab 5Cyclophosphamide 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5poly ICLC 4cabozantinib 4atezolizumab 4Oxaliplatin 4Gemcitabine 4Fluorouracil 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × capmatinib × 1 year × Clear all
NCT05110196 2026-04-07

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Novartis

Phase 4 Completed
50 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡